CC
NBIX icon

CQS Cayman’s Neurocrine Biosciences NBIX Stock Holding History

CQS Cayman’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-90,000
Closed -$5.09M – 124
2015
Q4 		$5.09M Buy
90,000
+71,800
+395% +$3.65M 0.35% 60
2015
Q3 		$724K Buy
+18,200
New +$880K 0.06% 128

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

CQS Cayman's NBIX Position: Q1 2016 in Review

CQS Cayman sold out of Neurocrine Biosciences (NBIX) in Q1 2016, closing a stake of 90,000 shares — an estimated $5.09M sold.

CQS Cayman first reported a position in NBIX in Q3 2015 and held it in 2 quarters. The position peaked at $5.09M in Q4 2015. 212 funds tracked by Wall St. Rank hold NBIX as of Q1 2016.

  • CQS Cayman reported no remaining Neurocrine Biosciences position as of Q1 2016 after selling out during the quarter.
  • CQS Cayman sold 90,000 Neurocrine Biosciences shares in Q1 2016, an estimated $5.09M.
  • CQS Cayman first reported a position in Neurocrine Biosciences in Q3 2015 and held it in 2 quarters.
  • CQS Cayman's Neurocrine Biosciences position peaked at $5.09M in Q4 2015.
  • 212 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2016.

Based on CQS Cayman's 13F filing for Q1 2016, filed 4 May 2016.